Skip to main content
Caplight Logo









Hinge Bio

Hinge Bio

Private
Burlingame, CaliforniaHealthcare & Life Scienceshttps://hingebio.com/

Last Round

Series A

Jan 15, 2025

Est. Valuation

$46M

Total Funding Raised

$30M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Hinge Bio is a biotechnology company that develops multispecific antibody therapeutics for autoimmune diseases, inflammatory diseases, and cancer using its proprietary GEM-DIMER™ platform.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting, Revenue Share

AI Layer

Non-AI

Keywords

multispecific antibodybiotechnologydrug discoveryantibody therapeuticsbiotechclinical-stage biotechantibody engineeringB cell-mediated diseasesdrug developmentlicensing agreementpharma partneringtherapeutic pipelinedrug pipelinepreclinical researchclinical trials

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Hinge Bio Comparables

Compare Hinge Bio with similar companies based on industry and business-model similarity.

Hinge Bio comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Candid Therapeutics
79%
Dren Bio
78%
Cullinan Oncology
77%

Hinge Bio Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AJan 15, 2025

Key People

Founding team and executive leadership

Carin Rollins

Co-Founder & COO

Founding Team

Barry Selick

Chief Executive Officer

Executive Team

Kristen Quigley

Chief Clinical Operations Officer

Executive Team

Hinge Bio Investors

Notable investors and investment history

Hinge Bio investors
InvestorRounds
Thornapple River CapitalSeries A
Ridgeback CapitalSeries A
InVivium CapitalSeries A
Point72Series A
Lightswitch CapitalSeries A
Point72 VenturesSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jun 20, 2026

    Monthly visitors increased 70% MoM.

  • Oct 13, 2025

    Regulatory milestone achieved for Lupus therapy, enabling clinical trials.

Hinge Bio Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Hinge Bio Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Hinge Bio's valuation, stock price, and market status.

Firmographic Details

HeadquartersBurlingame, California
Employee Range22
Year Founded2015
Last FundingJan 15, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?